Diabetes, hypertension, COVID-19 (SARS-CoV-2 infection) Not Applicable Diabetes mellitus, hypertensive diseases
Conditions
Interventions
This is a single-centre, observational prospective study with two groups for secondary outcome analysis: participants with an intact periodontium and those with periodontitis.
Clinica
Sponsors
University College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. At least 18 years of age and in good general health 2. A minimum of 20 teeth (not including dental implants) 3. Must voluntarily agree to sign the consent form
Exclusion criteria
Exclusion criteria: 1. Uncontrolled or currently undergoing treatment for systemic medical conditions (excluding diabetes and hypertension) including, but not limited to hepatic disease, renal disease, transmittable diseases, cancer, or HIV 2. On chronic treatment (defined as 2 weeks or more) of antibiotic, anti-inflammatory or anticoagulant therapy during the month preceding the baseline assessment 3. Self-reported pregnancy or lactation (due to possible oral tissue changes related to pregnancy and breastfeeding which can affect the interpretation of study results) 4. Concurrently participating in other clinical studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Prevalence of elevated HbA1c in the study population, measured using a point of care test (POCT) Quo-Test Analyser at baseline 2. Prevalence of elevated blood pressure in the study population, measured using an automated blood pressure machine at baseline 3. Prevalence of positive tests results for COVID-19 antigen and antibody tests in the study sample, measured with a BioCredit COVID-19 AG antigen test and a COVID-19 antibody test at baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Prevalence of elevated HbA1c in periodontitis patients compared to patients with an intact periodontium, measured using a point of care test (POCT) Quo-Test Analyser at baseline 2. Prevalence of elevated blood pressure in periodontitis patients compared to patients with an intact periodontium, measured using an automated blood pressure machine at baseline 3. Prevalence of elevated lipid profiles in the study population, measured with the Cardiocheck PA blood analyser at baseline 4. Prevalence of elevated lipid profiles in periodontitis patients compared to patients with an intact periodontium, measured with the Cardiocheck PA blood analyser at baseline 5. Prevalence of positive COVID-19 antigen or antibody test results in periodontitis patients compared to patients with an intact periodontium, measured with a BioCredit COVID-19 AG antigen test and a COVID-19 antibody test at baseline | — |
Countries
United Kingdom
Outcome results
None listed